Израел - Хебрејски - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1) 7.5 mcg / 0.5 ml - suspension for injection - influenza, inactivated, whole virus - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

Израел - Хебрејски - Ministry of Health

medici ltd - a/california/7/2009 (h1n1) 7.5 mcg/dose; a/victoria/361/2011 (h3n2) 7.5 mcg/dose - suspension for injection - influenza, inactivated, whole virus - for the prevention of influenza, particularly in children aged from 6 to 35 months who run an increased risk of associated complications.

Израел - Хебрејски - Ministry of Health

glaxo smith kline (israel) ltd - a/california/7/2009 (h1n1) 15 mcg / 0.5 ml; a/victoria/361/2011 (h3n2) 15 mcg / 0.5 ml - suspension for injection - influenza, live attenuated - prophylaxis of influenza, especially those who run an increased risk of associated complications. fluarix is indicated in adults and children from 6 months of age.

Израел - Хебрејски - Ministry of Health

medici ltd - diphtheria toxoid 15 lf / 0.5 ml; filamentous haemogglutinin (fha) 5 mcg / 0.5 ml - suspension for injection - hemophilus influenzae b, combinations with pertussis and toxoids - primary vaccination of infants, at or above the age of two months and as a booster in children up to their 6th birthday against diphtheria, tetanus, pertussis and invasive haemophilus influenzae type b infection.

Израел - Хебрејски - Ministry of Health

medici ltd - diphtheria toxoid 15 lf / 0.5 ml; filamentous haemogglutinin (fha) 20 mcg / 0.5 ml - suspension for injection - hemophilus influenzae b, combinations with pertussis and toxoids - primary vaccination of infants, at or above the age of two months and as a booster in children up to their 6th birthday against diphtheria, tetanus, pertussis, poliomyelitis and invasive haemophilus influenzae type b infections.

Израел - Хебрејски - Ministry of Health

abbott medical laboratories ltd, israel - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

Израел - Хебрејски - Ministry of Health

sanofi israel ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

Израел - Хебрејски - Ministry of Health

glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - תרחיף להזרקה - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen

Израел - Хебрејски - Ministry of Health

sanofi israel ltd - a/michigan/45/2015 (h1n1)pdm09 – like strain; a/singapore/infimh-16-0019/2016 (h3n2) - like virus; b/colorado/06/2017- like virus (b/victoria/2/87 lineage); b/phuket/3073/2013 like strain - תרחיף להזרקה - b/phuket/3073/2013 like strain 60 mcg / 0.7 ml; b/colorado/06/2017- like virus (b/victoria/2/87 lineage) 60 mcg / 0.7 ml; a/singapore/infimh-16-0019/2016 (h3n2) - like virus 60 mcg / 0.7 ml; a/michigan/45/2015 (h1n1)pdm09 – like strain 60 mcg / 0.7 ml - influenza, inactivated, split virus or surface antigen

Израел - Хебрејски - Ministry of Health

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 30 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.